Targets › F7
10 programs from 9 companies in 13 trials: 6 Phase 4, 4 Phase 3, 3 Phase 2; Hematology, Cardiovascular, Neurology; next expected readout Dec 2026.
Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. (UniProt, P08709)
Open in Phaseline: the race on F7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| American Thrombosis and Hemostasis Network | coagulation factor VIIa [recombinant]-jncw (SEVENFACT) Recombinant activated human factor VII (rhFVIIa) - cofactor for the extrinsic coagulation | F7 | Phase 4 | Hemophilia A With Inhibitor | Mar 2027 |
| Novo Nordisk | Eptacog Alfa (Activated) Coagulation factor VII exogenous protein | F7 | Phase 4 | Severe Postpartum Haemorrhage | Aug 2027 |
| Children's Hospital Los Angeles | Feiba Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f | F2, F7, F10 | Phase 4 | Hemophilia A With Inhibitor | – |
| CSL Behring | Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
| Joseph Broderick, MD | Recombinant Activated Factor VII (rFVIIa) Recombinant activated coagulation factor VII; promotes hemostasis by activating tissue fac | F7 | Phase 3 | Intracerebral Hemorrhage | Jan 2028 |
| Joseph Broderick, MD | Recombinant Factor VIIa (rFVIIa) Recombinant tissue factor pathway inhibitor; activates factor X to generate thrombin for h | F7 | Phase 3 | Intracerebral Hemorrhage | Jan 2029 |
| Icahn School of Medicine at Mount Sinai | Oral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation | F2, F7, F9, F10 | Phase 3 | Atrial Fibrillation | – |
| Emory University | Eptacog beta (SEVENFACT®; EB) Recombinant coagulation factor VIIa | F7 | Phase 2 | Glanzmann Thrombasthenia | Dec 2026 |
| Hemab ApS | Sutacimig Bispecific antibody binding activated factor VII and TLT-1 on platelets | F7, TREML1 | Phase 2 | Congenital Factor VII Deficiency | Nov 2027 |
| Northwell Health | FEIBA Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors | F2, F7, F9, F10 | Phase 2 | Cardiac Disease | Nov 2028 |
Hemophilia A With Inhibitor (2) Intracerebral Hemorrhage (2) Glanzmann Thrombasthenia (1) Severe Postpartum Haemorrhage (1) Congenital Factor VII Deficiency (1) Cardiac Disease (1) Atrial Fibrillation (1) Complex Cardiovascular Surgery With Cardiopulmonary Bypass (1) Cardiac Valve Disease (1) Hemophilia (1) Liver Cirrhosis (1)
small molecule (5), protein or peptide (4), antibody (1)
Joseph Broderick, MD (2) Emory University (1) Novo Nordisk (1) Hemab ApS (1) American Thrombosis and Hemostasis Network (1) Northwell Health (1) Icahn School of Medicine at Mount Sinai (1) CSL Behring (1) Children's Hospital Los Angeles (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.